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ABSTRACT

A synthetic catalyst providing superoxide dismutase activity
consists essentially of monodispersed nanoparticles of
cerium oxide having a crystal lattice containing cerium in
mixed valence states of Ce 3 + and Ce4 + wherein the Ce4 +
valence state predominates and containing an enhanced Ce3 + I
Ce4 + ratio and an effective number of oxygen vacancies in the
crystal lattice so as to increase catalytic efficiency. A method
of making the synthetic catalyst includes dissolving hydrous
Ce(N0 3 ) 3 in water so as to form a solution, stirring the solution, adding hydrogen peroxide, heating and stopping when
the solution develops a light yellow color.
18 Claims, 4 Drawing Sheets
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NANOPARTICLES OF CERIUM OXIDE
HAVING SUPEROXIDE DISMUTASE
ACTIVITY

in a living cell. Although there is growing evidence that ceria
nanoparticles impart protection to living cells, the molecular
mechanism of the antioxidant properties of cerium oxide
nanoparticles has yet to be elucidated. Previous studies have
suggested, based on observations of the impact of ceria nanoparticles on cultured cells, that ceria nanoparticles can act as
radical scavengers and redox cycling antioxidants.

RELATED APPLICATION
This application claims priority from co-pending provisional application Ser. No. 60/774,351, which was filed on
Feb. 17, 2006, and which is incorporated herein by reference
in its entirety.

SUMMARY OF THE INVENTION
10

STATEMENT OF GOVERNMENT RIGHTS
The invention was made with at least partial Government
support and the Government may certain rights in the invention, as specified by law.

15

FIELD OF THE INVENTION
The present invention relates to the field of nanotechnology
and, more particularly, to nanoparticles of cerium oxide
which provide the catalytic activity of superoxide dismutase
and to methods of making and using same.

20

BACKGROUND OF THE INVENTION

25

Cerium is a rare earth element of the lanthanide series. The
oxide form (Ce0 2 ) has routinely been used in polishing glass,
but current research is focused on use of cerium oxide nanoparticles in catalytic converters for automobile exhaust systems, oxygen sensors, an electrolyte for solid oxide fuel cells
or as an ultraviolet absorbent. While most of the rare earths
exist in a trivalent state (+3), cerium also occurs in a tetravalent (+4) state and may flip-flop between the two in a redox
reaction. It is established that cerium oxides make excellent
oxygen buffers, because of this redox capacity. As a result of
alterations in cerium oxidation state, cerium oxide forms
oxygen vacancies or defects in the crystal lattice structure by
loss of oxygen and/or its electrons. The valence and defect
structure of cerium oxide is dynamic and may change spontaneously or in response to physical parameters such as temperature, presence of other ions, and partial pressure of oxygen.
Studies have shown that with decrease in particle size,
cerium oxide nanoparticles show formation of more oxygen
vacancies within their crystal lattice. We hypothesized that
the increased surface area to volume in nanoparticles enables
Ce0 2 to regenerate its activity and thereby act catalytically. In
the case of transition metal oxides, a thorough analysis of
vacancies has lead to the understanding of the fundamental
nature of the catalytic reactivity. However, this knowledge
has been lacking with respect to the rare earth oxides. In
addition, there has been no reported literature elucidating the
molecular mechanism of any catalytic activity of these nanoparticles in biological systems.
Cerium oxide nanoparticles have a unique electron structure that is similar to chemical spin traps such as nitrosone
compounds and mixed valence state ceria nanoparticles have
been recently shown to apparently act as biological antioxidants. It has been proposed that this antioxidant activity is
mediated at oxygen vacancies at the surface of the nanoparticle. If so, then one cerium oxide nanoparticle may offer
many sites for catalysis, whereas pharmacological agents or
enzymes offer only one active site per molecule. In addition,
the electron defects in ceria nanoparticles may not be
destroyed after their initial reaction with reactive oxygen
species and thus these nanoparticles may be potent catalysts
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Disclosed herein is a synthetic catalyst providing superoxide dismutase activity. The synthetic catalyst comprises substantially monodispersed nanoparticles of cerium oxide having a crystal lattice containing cerium atoms in mixed valence
states of Ce 3 + and Ce4 + wherein the Ce4 + valence state predominates and having an effective number of oxygen vacancies in the crystal lattice.
Wishing not to be bound by the following explanation, the
synthetic catalyst is theorized to provide superoxide dismutase activity demonstrating a positive correlation with number of oxygen atom vacancies in the crystal lattice. Additionally, it is also theorized that the superoxide dismutase activity
has a positive correlation with content of Ce 3 + in the crystal
lattice.
Typical of the synthetic catalyst disclosed herein are substantially monodispersed nanoparticles of cerium oxide ranging in size from approximately 1 to 50 µm. Moreover, these
nanoparticles are preferably formed containing a ratio of
Ce 3 +/Ce4 + sufficiently large to provide a catalytic rate constant equal to or higher than the catalytic rate constant of
natural superoxide dismutase.
The invention also includes a method of making a synthetic
catalyst having superoxide dismutase activity and consisting
of a plurality of substantially monodispersed nanoparticles of
cerium oxide having a crystal lattice containing cerium in a
mixed valence state ofCe 3 + andCe4 +, wherein the superoxide
dismutase activity correlates with number of oxygen vacancies in the crystal lattice. A preferred method of the invention
includes dissolving hydrous Ce(N0 3 ) 3 in water so as to form
a solution, stirring the solution, adding 30% hydrogen peroxide solution and 30% ammonium hydroxide solution, and
heating until the solution develops a light yellow color; thereafter, the method stops. Preferably, in the method the water is
deionized and stirring is continuous. Also, it is preferable that
adding of the hydrogen peroxide be done rapidly while continuously stirring the solution. The hydrogen peroxide is preferably a 30% solution and the ammonium hydroxide is a 30%
solution; they are added in a proportion of 2:1 hydrogen
peroxide to ammonium hydroxide. Heating is best conducted
at approximately 150° C.
The invention further includes methods of using the disclosed synthetic catalyst. For example, a method of treating a
biological tissue to reduce oxidative stress comprises contacting the biological tissue with substantially monodispersed
nanoparticles of cerium oxide having a crystal lattice containing mixed valence states of Ce3 + and Ce4 + and sufficient
oxygen vacancies to effectively scavenge reactive oxygen
species before these contact the biological tissue. The biological tissue may include a tissue culture and the tissue may
comprise animal cells, mammalian cells or human cells.
Additionally, the invention includes a method of enhancing
cell longevity by contacting the cell with nanoparticles of
crystalline cerium oxide containing mixed valence states of
Ce 3 + and Ce4 + and bearing sufficient oxygen vacancies to
scavenge reactive oxygen species. Cells may also be protected against irradiation damage by contacting the cell with
substantially monodispersed nanoparticles of cerium oxide
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containing mixed valence states ofCe3 + and Ce4 + in a crystal
lattice having sufficient oxygen vacancies to effectively scavenge reactive molecular species generated by the irradiation.
Yet additionally, the invention includes a method of catalyzing conversion of superoxide into hydrogen peroxide by
contacting the superoxide with one or more nanoparticles of
cerium oxide having a crystal lattice containing mixed
valence states of Ce 3 + and Ce4 + and with sufficient oxygen
vacancies to function effectively as a synthetic equivalent to
superoxide dismutase.

cerium oxide nanoparticles. The sample B was prepared by
traditional homogeneous precipitation method. Ce(N0 3 )
3 .6H 2 0 was dissolved in deionized water and pre-determined
amount of ammonium hydroxide was added to the solution
with continuous stirring. The precipitate was separated and
dried at 80° C. and then calcined at 200° C. to obtain larger
particle size. The particles were then redispersed in acidic
water (1.5 pH) to obtain a stable dispersion of nanoparticles.
Transmission Electron microscopy of ceria nanostructures.
The particle morphology of ceria nanoparticles was studied
using high resolution transmission electron microscopy (HRTEM). Ceria nanoparticles were deposited on a carbon coated
copper grid for HRTEM analysis by the dipping method. The
HRTEM images of prepared particles were obtained with a
Philips (Tecnai Series) transmission electron microscope at
300 keV.
X-ray photoelectron spectroscopy. The surface chemistry
of the cerium oxide nanoparticles was studied using X-ray
photoelectron spectroscopy (XPS) using a 5400 PHI ESCA
(XPS) spectrometer. The base pressure during XPS analysis
was 10- 9 Torr and Mg-Ka X-ray radiation (1253.6 eV) at a
power of 200 watts was used. The binding energy of the Au
(4f712 ) at 84.0±0.1 eV was used to calibrate the binding
energy scale of the spectrometer. Any charging shift produced
in the spectrum by the sample was carefully removed by
taking C (ls) position (284.6 eV) as a reference line. Deconvolution of the XPS spectra was carried out using PeakFit
(Version 4) software.
X-ray diffraction (XRD) analysis. XRD analysis used
X-ray diffraction (Rigaku model) with a Cu Ka radiation and
operating conditions of 30 mA and 30 kV. The scanning rate
was 0.2 degree/min with a step size of0.01 degree.
Surface area measurements. The nanopowders of cerium
oxide were prepared by drying the dispersions of samples A
and B (prepared per the procedures given above). BET surface area of the nanopowders was obtained by physical
adsorption ofN2 at -196° C. using NOVA 4200e surface area
and pore size analyzer by Quantachrome Instruments. Prior to
the measurements, the samples were degassed for 3 hrs.
Generation of superoxide. Superoxide (0 2 -) was generated
by incubation of xanthine oxidase (Sigma, St. Louis, Mo.)
with hypoxanthine as substrate as previously described by
others. Hypoxanthine was present in all reactions at a concentration of 5 mM. To determine the level of superoxide
generated under these experimental conditions, the reduction
offerricytochrome C (Sigma, St. Louis, Mo.) was monitored
(change in absorbance at 550 nm) using a Spectramax 190
UV-visible spectrophotometer. Data were analyzed using
Softmax Pro 5 (Molecular Devices, Palo Alto, Calif.) and
SigmaPlot 8.0 (SPSS, Inc., Chicago, Ill.).
Detection ofhydrogen peroxide. Hydrogen peroxide levels
were assayed using Amplex Red kit from Molecular Probes
(Eugene, Oreg.). Amplex Red (10-acetyl-3,7-dihydroxyphenoxazine) is converted to a fluorescent resorufin compound
(excitation peak 571 nm, emission peak 585 nm) in the presence of hydrogen peroxide and horseradish peroxidase. Fluorescence of the resorufin compound was determined in white
microplates (96-well) using a Varian Cary Eclipse Spectrofluorometer (Varian, Palo Alto, Calif.) with excitation at 530
nm and emission at 590 nm. The excitation slit width was 5
nm, emission slit width set at 20 nm and a detector voltage of
400V.
SOD mimetic kinetic assays. Competition for reduction of
ferricytochrome C was utilized to assess the kinetics of the
SOD mimetic activity of cerium oxide nanoparticles. Superoxide was generated by hypoxanthine/xanthine oxidase at a
level that resulted in an absorbance change at 550 nm of

10

BRIEF DESCRIPTION OF THE DRAWINGS
Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunction with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. 1 is a Ce 3d high resolution XPS analysis revealing
higher Ce 3 + levels in sample A as compared to sample B,
according to an embodiment of the present invention;
FIG. 2 shows line graphs of SOD mimetic activity of ceria
nanoparticles assayed using ferricytochrome C;
FIG. 3 shows high-resolution transmission electron
microscopy (HRTEM) images of nanoceria preparations; and
FIG. 4 shows that X-ray diffraction (XRD) analysis reveals
a fluorite crystal structure for both preparations (A and B) of
ceria nanoparticles.
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DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENT
The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein could be used in the practice or
testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, or other references mentioned herein are incorporated by reference in their entirety. In case of conflict,
however, the present specification, including any definitions,
will control. In addition, it should be understood that the
materials, methods and examples given are illustrative in
nature only and not intended to be limiting. Accordingly, this
invention may be embodied in many different forms and
should not be construed as limited to the illustrated embodiments set forth herein. Rather, these illustrated embodiments
are provided so that this disclosure will be thorough and
complete, and will fully convey the scope of the invention to
those skilled in the art. Other features and advantages of the
invention will be apparent from the following detailed
description, and from the claims.
Methods and Materials
Ceria nanoparticles preparation. The ceria nanoparticles
were synthesized by wet chemical process. All the chemicals
were obtained from Sigma-Aldrich Chemicals Inc. For preparation of sample A, Ce(N0 3 ) 3 .6H 2 0 was dissolved in deionized water and 2 ml of30% H 2 0 2 and 1 ml of30% ammonium
hydroxide was rapidly added with stirring at about 300 rpm.
The solution was then heated at 150° C. with continuous
stirring to obtain a light yellow colored stable dispersion of
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approximately 0.025 units per minute. Reactions were carried
out in 96-well plates and contained 100 µL total volume.
CuZnSOD (Sigma, S8160, St. Louis, Mo.) was utilized as an
internal control. Assays were carried out in Tris buffer (50
mM Tris-HCl, pH 7 .5) at room temperature and the change in
absorbance (550 nm) was monitored using a Spectramax 190
UV-visible spectrophotometer (Molecular Devices, Sunnyvale, Calif.). In reactions containing lower amounts of superoxide (ll550 nm<0.005/minute) no catalase was included.
Reactions with higher levels of superoxide (ll550 nm 20.025/
minute) 2,000 units of catalase were added to eliminate the
reaction of ferricytochrome C (or nanoparticles) with hydrogen peroxide generated as a result of the SOD mimetic activity.
We tested the ability of mixed valence state ceria nanoparticles, with higher levels of Cerium in the 3+ state, to react
with superoxide in vitro. Since it has been proposed that
surface oxygen vacancies can mediate catalysis on ceria
nanostructures, and that higher ratio of Ce 3 +/Ce4 + in nanoparticles preparation correlates with higher oxygen and electron vacancy, we tested two batches of ceria nanoparticles for
their ability to react with superoxide.
Next we used X-ray diffraction (XRD) analysis (FIG. 2) to
confirm that both preparations of ceria nanoparticles contain
a fluorite crystal lattice. Peak broadening in sample A confirmed smaller particle size compared to sample B, which is
consistent with the HRTEM analysis. The measured BET
(Brunauer Emmett Teller) surface areas were also consistent
with the HRTEM and XRD measurements. The specific surface areas of the samples A and B were found to be 140 and
115 m 2 /g, respectively. The Ce (3d) XPS spectra shown in
FIG. 1 demonstrate the presence of a mixed valence state
(Ce3 + and Ce4 +) for both preparations. As shown in FIG. 1, the
peaks between 875-895 eV correspond to Ce 3d512 , between
895-910 eV correspond to Ce 3d3/2 and peak at 916 eV is a
characteristic satellite peak indicating the presence of +4
states. The peaks at 880.2, 885.0, 899.5 and 903.5 eV are
indicative of +3 peaks as opposed to 882.1, 888.1, 898.0,
900.9, 906.4 and 916.40 eV indicating the presence of +4
states. Note, the population density of +3 states in Sample A
is higher than in Sample B. Higher intensity peaks corresponding to Ce 3 + were observed in sample A, indicating a
higher Ce 3 +/Ce4 + ratio in this sample. The Ce (3d) XPS
spectra were deconvoluted as described previously by S.
Deshpande, S. Patil, S. Kuchibhatla and S. Seal, Applied
Physics Letters, 2005, 87, and the concentration ofCe 3 + was
calculated using the following equation:

ceria crystal. Arrows indicate the orientation of the nanoparticles on the TEM grid in specific direction found by determining the distance between the two parallel lines (0.312 nm
for 111 and 0.270 nm for 200 plane).
FIG. 4 shows that XRD analysis reveals a fluorite crystal
structure for both preparations (A and B) of ceria nanoparticles. The XRD spectrum for Sample A shows broader peaks
than Sample B indicating smaller particle size in the former.
Also, the peaks are relatively sharper in Sample B and the 200
peak is more succinct.
We then tested whether nanoceria would affect the level of
hydrogen peroxide produced in the presence of superoxide
(generated from hypoxanthine/xanthine oxidase). We
observed a significant increase in hydrogen peroxide levels
produced in the presence of ceria nanoparticles using a
coupled horseradish peroxidase assay (data not shown). This
increase was observed in both preparations of nanoparticles,
but the apparent increase was more dramatic with preparation
A. Since we had observed increases in hydrogen peroxide
production in the presence of ceria nanoparticles and superoxide, we then tested the activity of ceria nanoparticles in a
classic SOD activity assay~ompetition with cytochrome C
for reduction by superoxide. Ferricytochrome C reduction
was followed spectrophotometrically by measuring the
increase in absorbance at 550 nm. Two thousand units of
catalase were added to the reaction to efficiently remove
hydrogen peroxide and avoid side reactions with ferricytochrome C or ceria nanoparticles. Ceria nanoparticle concentrations were determined by calculating the average diameter
of particles (using TEM, above FIG. 1) in the preparation, and
conversion to particle concentration based on total ceria in
solution. FIG. 2A shows results when CuZnSOD was added
to a reaction where reduction of ferricytochrome C was
occurring at a rate of 0.025/minute (A550 nm). One unit of
CuZnSOD corresponds to an enzyme concentration of 120
nM. FIG. 2B shows the results of adding ceria nanoparticle
preparation A at 15, 30, 45 and 60 nM concentrations. FIG.
2C depicts results when ceria nanoparticles preparation B
was added at 5, 15 and 25 nM concentrations. A representative experiment is shown from at least six replicates of each
concentration of cerium nanoparticles where the resulting
change in the slope of the line (compared to control) varied by
less than 20%. Indeed, nanoparticle preparation A efficiently
competed with ferricytochrome C for reduction by superoxide (FIG. 2B) in a concentration dependent manner. Preparation B Also Displayed Some Sod Mimetic Activity as Well,
But this was far less efficient, as indicated by the poor competition with ferricytochrome C (FIG. 2C). Addition ofEDTA
at concentrations up to 5 mM did not alter the activity, confirming that adventitious iron or other metal was not catalyzing the activity (data not shown). The concentration of
SOD in the reaction shown in FIG. 6A (1 unit addition) is 120
nM. Since this is significantly higher than the particle concentration, this supports the conclusion that each nanoceria
molecule is a more efficient catalyst than SOD.
Using a comparative method for SOD kinetic analysis previously described and the known rate constant for reduction
offerricytochrome C by natural superoxide dismutase at pH
7.2 (1.lxl05 M- 1 sec- 1 ), we determined the catalytic rate
constant for nanoceria preparation A (with respect to the
average nanoparticle) to be 3.6xl09 M- 1 sec- 1 . The most
recent kinetic analysis of CuZn SOD calculated a rate constant for SOD between 1.3 and2.8xl09 M- 1 sec- 1 , depending
on the reaction conditions. Thus a single ceria nanoparticle is
more efficient as an SOD catalyst than the authentic enzyme
itself. Nanoparticles have larger surface energy due to a large
surface to volume ratio, and this property makes them more

[Ce3+] - Avo +Av'

Avo +Av' + Auo +Au'
+ Auo +Au' +Av +A~ +A~ +Au +A~ + Azi

The Ce3 + concentration in sample A was found to be 40
atom% while that in sample B was 22 atom%. These results
are in line with our earlier studies of size dependent changes
in valence state of cerium oxide nanoparticles which indicated increase in Ce 3 + with decrease in particle size. These
two nanoparticles preparations allowed us to compare ceria
preparation with varying surface chemistry for their potential
interaction with superoxide.
FIGS. 3A and 3B show HRTEM images ofCe0 2 nanoparticle sample A indicating particle size of 10-15 nm with 3-5
nm crystals present and Ce0 2 nanoparticle sample B showing
particle size of 5-8 nm, respectively. The parallel lines
observed in each individual ceria nanoparticle are the lattice
fringes formed due to periodical arrangement of atoms in the
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reactive compared to their bulk counterparts. Cerium oxide
nanoparticles form oxygen vacancies by giving out oxygen
from their crystal lattice. Previous studies have shown that
size of ceria nanoparticles negatively correlates with the ratio
of Ce3+/Ce4+. The experimental evidence presented here
clearly demonstrate that ceria nanoparticles with higher
Ce3+/Ce4+ ratio catalyze SOD mimetic activity, yet the
molecular mechanism behind this catalysis is still unknown.
The SOD mimetic activity exhibited by the vacancy engineered ceria nanoparticles is likely to be the mechanism of
action for data previously presented that showed protection of
cells against ROS or demonstrated a lifespan extension with
treatment with ceria nanoparticles.
Although the 'active site' of the ceria nanoparticle has yet
to be firmly established, one can speculate on the reaction
mechanism based on that known for SOD. Similarly to Fe and
Mn-SOD it is possible that the dismutation of superoxide by
ceria nanoparticles may be catalyzed as follows, although the
inventors wish not to be bound to this proposed explanation:

8
6. A method of making a synthetic catalyst having super-
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Catalysis could occur at the same cerium atom (as in the
case with the metal-dependent SOD) or independently at
different oxygen vacancy sites.
Accordingly, in the drawings and specification, there has
been disclosed a typical preferred embodiment of the invention, and although specific terms are employed, the terms are
used in a descriptive sense only and not for purposes of
limitation. The invention has been described in considerable
detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
That which is claimed:
1. A synthetic catalyst providing superoxide dismutase
activity, said synthetic catalyst comprising substantially
monodispersed nanoparticles of cerium oxide having a crystal lattice containing cerium atoms in mixed valence states of
Ce 3 + and Ce4 +, the crystal lattice containing a ratio ofCe3 +/
Ce4 + sufficiently large to provide a catalytic rate constant
equal to or higher than the catalytic rate constant of natural
superoxide dismutase.
2. The synthetic catalyst of claim 1, wherein the superoxide
dismutase activity is provided at a catalytic rate higher than
1.lxl05 M- 1 sec- 1 .
3. The synthetic catalyst of claim 1, wherein the superoxide
dismutase activity is provided at a catalytic rate of approximately 3.6x109 M- 1 sec- 1 than1.lxl05 M- 1 sec- 1 .
4. The synthetic catalyst of claim 1, wherein the nanoparticles range in size from approximately 1 to 50 µm.
5. The synthetic catalyst of claim 1, wherein the Ce4 +
valence state predominates.

25

30

35

40

45

50

oxide dismutase activity and consisting of a plurality of substantially monodispersed nanoparticles of cerium oxide having a crystal lattice with containing cerium in a mixed valence
state of Ce3 + and Ce4 + wherein the superoxide dismutase
activity correlates with number of oxygen vacancies in the
crystal lattice, the method comprising:
dissolving hydrous Ce(N0 3 ) 3 in water so as to form a
solution;
stirring the solution;
adding hydrogen peroxide and ammonium hydroxide;
heating the solution; and
stopping when the solution develops a light yellow color.
7. The method of claim 6, wherein the water is deionized.
8. The method of claim 6, wherein stirring is continuous.
9. The method of claim 6, wherein adding is done rapidly
and comprises 30% hydrogen peroxide and 30% ammonium
hydroxide.
10. The method of claim 6, wherein heating is at approximately 150° C.
11. A method of treating a biological tissue to reduce
oxidative stress, the method comprising contacting the biological tissue with substantially monodispersed nanoparticles
of cerium oxide having a crystal lattice containing mixed
valence states ofCe 3 + and Ce4 + and sufficient oxygen vacancies to effectively scavenge reactive oxygen species so as to
reduce oxidative stress on the biological tissue.
12. The method of claim 11, wherein the biological tissue
comprises a tissue culture.
13. The method of claim 11, wherein the biological tissue
comprises animal cells.
14. The method of claim 11, wherein the biological tissue
comprises mammalian cells.
15. The method of claim 11, wherein the biological tissue
comprises human cells.
16. A method of enhancing cell longevity, the method
comprising contacting the cell with substantially monodispersed nanoparticles of crystalline cerium oxide containing
mixed valence states of Ce3 + and Ce4 + and bearing sufficient
oxygen vacancies to scavenge reactive oxygen species.
17. A method of protecting a cell against irradiation damage, the method comprising contacting the cell with substantially monodispersed nanoparticles of cerium oxide containing mixed valence states of Ce 3 + and Ce4 + in a crystal lattice
having sufficient oxygen vacancies to effectively scavenge
reactive molecular species generated by the irradiation.
18. A method of catalyzing conversion of superoxide into
hydrogen peroxide, the method comprising contacting the
superoxide with one or more nanoparticles of cerium oxide
having a crystal lattice containing mixed valence states of
Ce 3 + and Ce4 + and with sufficient oxygen vacancies to function effectively as a synthetic equivalent to superoxide dismutase.
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